BREAKING! Coronavirus Research Shows That Arbidol Could Help In Post-Exposure Prophylaxis (PEP) Of Covid-19 Transmission Among Healthcare Workers
: (Warning, the following article is based on a research article from China and warrants further study. We cannot ascertain if studies published by the China state authorities and Chinese Academy Of Sciences are peer-reviewed as China as a different methodology when it comes to having medical and science studies published online. Further to this, we strongly advise any individuals against trying to procur any drugs online or through illegal channels and to treat or prevent the Covid-19 disease by themselves. Always consult a licensed medical doctor or your nearest healthcare facility.)
A research conducted by Dr Hu Bo from the Huazhong University of Science and Technology in Wuhan that despite being published in the journals of the Chinese Academy of Sciences on the 26th
Of February 2020 was only released online today a few hours ago (There are more than 279 research papers on the SARS-CoV-2 coronavirus conducted by Chinese researchers that have yet to have been made available to the global community) indicates that the usage of a pharmaceutical compound called arbidol could possibly act as a post-exposure prophylaxis (PEP) of Covid-19 transmission among healthcare workers. (http://www.chinaxiv.org/abs/202002.00065
The researchers observed that during the initial stages of the SARS-CoV-2 coronavirus outbreak in China, many healthcare workers including doctors, nurses and supporting healthcare staff were contracting the new coronavirus themselves despite the usage of protective gear and precautions. Furthermore other studies also indicated that hospital transmissions were also a major source of the spread. (https://www.thailandmedical.news/news/medical-blunders-:-hospital-associated-transmission--are-major-cause-of-infections-in-china-according-to-jama-study
Based on earlier vitro studies and clinical assessments, the researchers conducted two cohort studies involving 27 families and 124 healthcare workers who had high risk of exposure to the Covid-19 disease, using Arbidol, Oseltamivir and placebo for the different sub-groups for each of the cohorts. After a period of 24 days and using standard nucleic acid diagnostic platforms, it was found that those that used Arbidol reported an extremely low number of cases contracting the Covid-19 disease whereas those using Oseltamivir had no effect in preventing transmissions.
Though the studies had a number of limitations and warrants further research, most healthcare facilities in China have already adopted the usage of Arbidol as a standard protocol for post-exposure prophylaxis (PEP) Of Covid-19 transmission among its healthcare workers.
Arbidol or Umifenovir, is a broad-spectrum antiviral only available in China and Russia and was previously used against certain influenza outbreaks in the past.
Chemically, umifenovir features an indole core, functionalized at all but one positions with different substituents. The drug is claimed to inhibit viral entry into target cells and stimulate the immune response.
In February 2020, Li Lanjuan, an expert of the National Health Commission of China, proposed using Arbidol (umifenovir) together with darunavir as a potential treatment during the 2019–20 coronavirus outbreak. Chinese experts claim that preliminary tests had shown that arbidol and darunavir could inhibit replication of the virus. (https://www.jstage.jst.go.jp/article/bst/advpub/0/advpub_2020.01020/_article
However, later studies showed that it did not show any efficacy in treating the Covid-19 disease. (http://rs.yiigle.com/yufabiao/1182592.htm
However usage by itself as a post-exposure prophylaxis (PEP) of Covid-19 transmission has been demonstrating positive results though further research is still warranted.
For more on the coronavirus research
, keep logging on to Thailand Medical News
Please also help share our site and articles online as being a poor entity that is not profit orientated, we do not have any support from any Thai Government or private companies as most Thai companies and corporations do not think that health of medical issues are of importance as they are more busy with their own greed. We also do not also get any support from the local private hospitals, pharma companies or medical related organisations, hence we do not have monies to pay American social media platforms like Facebook, LinkedIn and Twitter whose local offices and regional offices in Singapore, Thailand, and India will lower your feed exposure as you are not advertising with them. For example with LinkedIn, though we have like 12,000 followers on our personal acct,but less than 200 can actually see our daily news postings as LinkedIn lowers the feed. We have the same problem with Twitter as well . We are basically a Thai medical mediatech and general mediatech startup that has never received any support from any entities in Thailand due to the prevalence of nepotism, corruption and also ego and incompetence on the part of certain senior executives and also the fact that Thais do not know how to collaborate and work together!
We like to thank the 3.2 million odd regular readers who have been following us so far.